Dey, A;
              
      
        
        
  
(2016)
  Enhancing the neutrophil-mediated anti-cancer response after oncolytic measles virus therapy in B cell malignancy: dissecting out the mechanism.
    Doctoral thesis , UCL (University College London).
  
  
       
    
  
| Preview | Text Final thesis Aditi Dey 2016 submitted .pdf - Accepted Version Download (3MB) | Preview | 
| ![[thumbnail of Chapter 5 videos in pp.pptx]](https://discovery.ucl.ac.uk/style/images/fileicons/slideshow.png) | Slideshow Chapter 5 videos in pp.pptx - Supplemental Material Download (46MB) | 
Abstract
Oncolytic measles virus (MV) is being tested in several ongoing clinical trials with encouraging results. There is a demonstrable need to explore the role of the immune system in addition to the direct oncolytic effect of MV. My laboratory has previously shown that neutrophils are involved in MV-mediated tumour regressions, becoming activated, upon MV infection. This thesis further explores the role of neutrophils, one of the key players of the innate immune system in MV oncolysis. First, I showed that acute lymphoblastic leukaemia (ALL) shows marked sensitivity to MV oncolysis (Patel, Dey et al., 2011). I attempted to enhance neutrophil function at tumour sites by generating a novel strain of MV expressing the human granulocyte colony-stimulating factor (GCSF), a known neutrophil survival factor and enhancer of antibody dependent cellular cytotoxicity (ADCC). Evaluating the effects in two different models of B-cell malignancy, I showed that neutrophil depletion abrogated the MV therapeutic effect in an in-vivo Raji - but not Nalm-6 - tumour model. MVhGCSF enhanced the oncolytic capacity of MV in the Raji model in-vivo, whereas in the Nalm-6 model, the opposite was unexpectedly the case. MVhGCSF replicated within an MV-infectable CD46 transgenic mouse model with detectable serum levels of hGCSF but no toxicity. My data suggest that a "one-size-fits-all" model of immune response to viral oncolysis is not appropriate, and each tumour target will need full characterisation for the potential of MV to generate benefit (Dey et al., 2016). 5 Next, I showed that ADCC was NOT a mechanism by which neutrophils kill MV-infected cells. Finally, I showed that MV infection of target cells can stimulate neutrophils to develop a cytotoxic effector phenotype, all aspects of which are blocked by fusion inhibition. Hence, I suggest a new mechanism for MV-mediated oncolysis; fusion between infected target cells and neutrophils.
| Type: | Thesis (Doctoral) | 
|---|---|
| Title: | Enhancing the neutrophil-mediated anti-cancer response after oncolytic measles virus therapy in B cell malignancy: dissecting out the mechanism | 
| Event: | UCL | 
| Open access status: | An open access version is available from UCL Discovery | 
| Language: | English | 
| Keywords: | Gene therapy, oncolytic virus, B cell malignancy, Neutrophils | 
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology | 
| URI: | https://discovery.ucl.ac.uk/id/eprint/1521057 | 
Archive Staff Only
|  | View Item | 
 
                      
